High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy

Molecular Vision

Volumn 17, Issue , 2011, Pages 1829-1838

  El Asrar, Ahmed M Abu ^a   Nawaz, Mohd Imtiaz ^a   Kangave, Dustan ^a   Geboes, Karel ^b   Ola, Mohammad Shamsul ^a   Ahmad, Saif ^c   Al Shabrawey, Mohamed ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETINA HEMORRHAGE; RETINA NEOVASCULARIZATION; UPREGULATION; VITRECTOMY; VITREOUS BODY; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CHEMOKINE CCL2; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; RETINA; RETINAL NEOVASCULARIZATION; VITRECTOMY; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 79960729070     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS. Adamis AP. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18:1450-2
2. Miyamoto K, Khosrof S, Brusell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999; 96:10836-41.
3. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11:91-9
4. Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw 2006; 17:155-65
5. Abu el-Asrar AM, Van Damme J, Put W, Veckeneer M, Dralands L, Billiau A, Missotten L. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol 1997; 123:599-606
6. Barile GR, Chang S, Park L, Reppucci VS, Schiff WM, Schmidt AM. Soluble cellular adhesion molecules in proliverative vitreoretinopathy and proliferative diabetic retinopathy. Curr Eye Res 1999; 19:219-27
7. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009; 116:73-9
8. Adamiec-Mroczek J, Oficjalska-Mlynczak J. Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetesrole of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246:1665-70
9. Treutiger CJ, Mullins GE, Johansson ASM, Rouhiainen A, Rauvala HME, Eriandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmbld JEW. High mobility group 1B-box mediates activation of human endothelium. J Intern Med 2003; 254: 375-385
10. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101:2652-60
11. Luan ZG, Zhang H, Yang PT, Ma XC, Zhang C, Guo RX. HMGB1 activates nuclear factor-?B signaling by RAGE and increases the production of TNF- a in human umbilical vein endothelial cells. Immunobiology 2010; 215:956-62.
12. Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M, Melloni E, Presta M. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006; 176:12-5.
13. Schlueter C, Weber H, Meyer B, Rogalla P, Röser K, Hauke S, Bullerdiek J. Angiogenetic signaling through hypoxia. HMGB1: an angiogenic switch molecule. Am J Pathol 2005; 166:1259-63
14. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P, Zeiher AM, Chavakis T, Dimmeler S. Highmobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007
15. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, Griffiioen AW. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006; 108:2339-48
16. Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A, Yamamoto K, Kuniyasu H. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 2007; 450:287-95
17. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: Therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010; 79:1379-86.
18. Al-Shabrawey M, Rojas M, Sanders T, Behzadian A, El-Remessy A, Bartoli M, Parpia AK, Liou G, Caldwell RB. Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci 2008; 49:3239-44
19. Arimura N, Ki-i Y, Hashiguchi T, Kawahara K, Biswas K, Nakamura M, Sonoda Y, Yamakiri K, Okubo A, Sakamoto T, Maruyama I. Intraocular expression and release of highmobility group box 1 protein in retinal detachment. Lab Invest 2009; 89:278-89
20. El-Asrar AM, Missotten L, Geboes K. Expression of highmobility group box-1/ receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes. Mol Vis 2011; 17:508-18
21. Soro-Paavonen A, Watson AMD, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57:2461-9
22. Li F, Yang N, Zhang L, Tan H, Huang B, Liang Y, Chen M, Yu X. Increased expression of toll-like receptor 2 in rat diabetic nephropathy. Am J Nephrol 2010; 32:179-86
23. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010; 59:249-55
24. El-Asrar AM, Missotten L, Geboes K. Expression of cyclooxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol 2008; 92:1534-9
25. Dragomir E, Simionescu M. Monocyte chemoattractant protein-1 - a major contributor to the inflammatory process associated with diabetes. Arch Physiol Biochem 2006; 112:239-44
26. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein -1-induced angiogenesis is mediated by vascular endothelial factor-A. Blood 2005; 105:1405-7.
27. Kim MY, Byeon CW, Hong KH, Han KH, Jeong S. Inhibition of angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide. FEBS Lett 2005; 579:1597-601
28. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14:506-12
29. Targher G, Bertolini L, Zoppinit G, Zenari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 2005; 22:999-1004
30. Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CD, Parving HH, Rossing P. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years. Diabetes Care 2008; 31:1170-6.
31. Schaumberg DA, Glynn RJ, Jenkins AJ, Iyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 2005; 111:2446-53.
32. Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson BI, Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology 2009; 48:1190-6
33. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 2007; 48:858-65.
34. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Hörig H, Hudson BI, Qu W, Weinberg AD, Yan SF, Schmidt AM. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46:2916-24
35. Pullerits R, Bokarewa M, Dahlberg L, Tankowski A. Decreased levels of soluble receptor for advanced glycatin end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005; 7:R817-24
36. Qiu J, Nishimura M, Wang Y, Sims IR, Qiu S, Savitz SI, Salomone S, Moskowitz MA. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008; 28:927-38
37. Kim JB, Lim CM, Yu YM, Lee JK. Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the post ischemic rat brain. J Neurosci Res 2008; 86:1125-31
38. Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW, Lee MH, Han PL, Park JS, Lee JK. HMGB1, a novel cytokinelike mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006; 26:6413-21
39. Kawabata H, Setoguchi T, Yone K, Souda M, Yoshida H, Kawahara K, Maruyama I, Komiya S. High mobility group box 1 is upregulated after spinal cord injury and is associated with neuronal cell apoptosis. Spine (Phila Pa 1976) 2010; 35:1109-15
40. Pedrazzi M, Raiteri L, Bonanno G, Patrone M, Ledda S, Passalacqua M, Milanese M, Melloni E, Raiteri M, Pontremoli S, Sparatore B. Stimulation of excitatory amino acid release from adult mouse brain glia subcellular particles by high mobility group box 1 protein. J Neurochem 2006; 99:827-38
41. Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, Sparatore B, Moroni F, Chiarugi A. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 2007; 103:590-603